Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells
- PMID: 15746436
- DOI: 10.1161/01.ATV.0000161420.55482.ef
Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells
Abstract
Objective: Recent research suggests a central role for CD40 ligand (CD40L) in atherogenesis. However, the relevant cellular source of this proinflammatory cytokine remains unknown. To test the hypothesis that CD40L expressed on hematopoietic cell types (eg, macrophages, lymphocytes, platelets) is crucial to atherogenesis, we performed bone marrow reconstitution experiments using low-density receptor-deficient (ldlr-/-) and ldlr-/-/cd40l-/- compound-mutant mice.
Methods and results: As expected, systemic lack of CD40L in hypercholesterolemic ldlr-/- mice significantly reduced the development of atherosclerotic lesions in the aortic arch, aortic root, and abdominal aorta compared with ldlr-/- mice. Furthermore, atheromata in ldlr-/-/cd40l-/- mice showed reduced accumulation of macrophages and lipids and increased content in smooth muscle cells and collagen compared with ldlr-/- mice. Surprisingly, reconstitution of irradiated ldlr-/- mice with ldlr-/-/cd40l-/- bone marrow did not affect the size or composition of atherosclerotic lesions in the root or arch of hypercholesterolemic ldlr-/- mice. Moreover, lipid deposition in the abdominal aorta diminished only marginally compared with mouse aortas reconstituted with ldlr-/- bone marrow.
Conclusions: These experiments demonstrate that CD40L modulates atherogenesis, at least in mice, primarily by its expression on nonhematopoietic cell types rather than monocytes, T lymphocytes, or platelets, a surprising finding with important pathophysiologic and therapeutic implications.
Comment in
-
CD40 ligand: not bad to the bone (marrow), after all.Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1088-90. doi: 10.1161/01.ATV.0000169538.64914.70. Arterioscler Thromb Vasc Biol. 2005. PMID: 15923539 No abstract available.
Similar articles
-
Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice.Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1647-53. doi: 10.1161/01.ATV.0000173413.31789.1a. Epub 2005 Jun 9. Arterioscler Thromb Vasc Biol. 2005. PMID: 15947238
-
Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice.Circulation. 2004 Jun 29;109(25):3149-53. doi: 10.1161/01.CIR.0000134704.84454.D2. Epub 2004 Jun 14. Circulation. 2004. PMID: 15197138
-
Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.Circulation. 2007 Sep 18;116(12):1404-12. doi: 10.1161/CIRCULATIONAHA.106.684704. Epub 2007 Aug 27. Circulation. 2007. PMID: 17724261
-
The multi-functionality of CD40L and its receptor CD40 in atherosclerosis.Thromb Haemost. 2009 Aug;102(2):206-14. doi: 10.1160/TH09-01-0029. Thromb Haemost. 2009. PMID: 19652870 Review.
-
CD40 and its ligand in atherosclerosis.Trends Cardiovasc Med. 2007 May;17(4):118-23. doi: 10.1016/j.tcm.2007.02.004. Trends Cardiovasc Med. 2007. PMID: 17482093 Review.
Cited by
-
Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans.PLoS One. 2010 Jul 14;5(7):e11589. doi: 10.1371/journal.pone.0011589. PLoS One. 2010. PMID: 20644648 Free PMC article.
-
T-cell costimulation and coinhibition in atherosclerosis.Circ Res. 2008 Nov 21;103(11):1220-31. doi: 10.1161/CIRCRESAHA.108.182428. Circ Res. 2008. PMID: 19028921 Free PMC article. Review.
-
Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis: Therapeutic _targets in Atherosclerosis?JACC Basic Transl Sci. 2024 Mar 13;9(6):827-843. doi: 10.1016/j.jacbts.2023.12.007. eCollection 2024 Jun. JACC Basic Transl Sci. 2024. PMID: 39070270 Free PMC article. Review.
-
Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review.J Am Coll Cardiol. 2022 Feb 15;79(6):577-593. doi: 10.1016/j.jacc.2021.11.048. J Am Coll Cardiol. 2022. PMID: 35144750 Free PMC article. Review.
-
Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state.Cardiovasc Res. 2023 May 22;119(5):1146-1160. doi: 10.1093/cvr/cvac084. Cardiovasc Res. 2023. PMID: 35587037 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials